pentoxifylline tablet, extended release
state of florida doh central pharmacy - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline extended-release tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline extended-release tablet should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
trental 400 pentoxifylline (oxpentifylline) 400 mg modified release tablet blister pack
clinect pty ltd - pentoxifylline, quantity: 400 mg - tablet, modified release - excipient ingredients: povidone; hyetellose; titanium dioxide; hypromellose; erythrosine; purified talc; macrogol 8000; magnesium stearate - treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. trental 400 can thus improve function and symptoms but is not intended to replace more definitive therapy, such as vascular surgery, or removal of arterial obstructions when treating peripheral vascular disease.
aspen pentoxifylline 400 sr
pharmacare limited - pentoxifylline - tablet - each tablet contains pentoxifylline 400,0 mg
trental 400 film-coated tablet 400 mg
sanofi-aventis singapore pte. ltd. - pentoxifylline - tablet, film coated - 400 mg - pentoxifylline 400 mg
trental 400 modified-release tablets
mawdsley-brooks & company ltd - pentoxifylline - modified-release tablet - 400mg
pentoxifylline tablet, extended release
major pharmaceuticals - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline- pentoxifylline tablet, extended release
preferred pharmaceuticals, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet film coated extended release
mckesson contract packaging - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg
pentoxifylline tablet film coated extended release
cardinal health - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg
pentoxifylline tablet film coated extended release
cardinal health - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg